• PD-1 antibody | Pancreatic cancer PD-1 antibody therapy has had limited success in pancreatic cancer due to the tumor's unique biology and immunosuppressive microenvironment. However, ongoing research into combination therapies, stromal modulation, and biomarker-driven approaches holds promise for improving outcomes in this difficult-to-treat cancer. Despite these challenges, there has been ongoing research into the use of PD-1 and PD-L1 inhibitors in pancreatic cancer, often in combination with other therapies. PD-1 inhibitors like pembrolizumab (Keytruda) and nivolumab (Opdivo) have been tested as monotherapies in pancreatic cancer with disappointing results. Most clinical trials have reported low response rates and minimal impact on survival when these agents are used alone. Ongoing research into the use of PD-1 and PD-L1 inhibitors in pancreatic cancer, in combination with other therapies: chemotherapy, radiation therapy, targeted therapies; other immunotherapies, stromal modulation: